Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-invasive assessment of muscle compartment elasticity by pressure-related ultrasound in pediatric trauma: a prospective clinical study in 25 cases of forearm shaft fractures.

European journal of medical research·2023
Same author

PREVALENCE AND CHARACTERISTICS OF THE POLYCYSTIC OVARIAN SYNDROME IN OVERWEIGHT AND OBESE PREMENOPAUSAL WOMEN.

Acta endocrinologica (Bucharest, Romania : 2005)·2023
Same author

Djeho, the Egyptian God's dancer with dwarfism from the thirtieth dynasty.

Journal of endocrinological investigation·2023
Same author

Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study.

Pituitary·2022
Same author

[How to explore... hyperandrogenism associated with insulin resistance ? An example based on the HAIR-AN syndrome.]

Revue medicale de Liege·2021
Same author

An Infundibular Unidentified Object (IUO): a new pituitary stalk marker?

Pituitary·2021
Same journal

lncRNA PANDAR predicts adverse pregnancy outcomes and reflects hyperglycemia-associated cellular stress in gestational diabetes mellitus.

Journal of endocrinological investigation·2026
Same journal

Correction: Early in, early out: reproductive lifespan timing and cardiometabolic risk in women.

Journal of endocrinological investigation·2026
Same journal

Adult mice are more susceptible to high-fat diet-induced visceral adiposity and insulin resistance than juvenile mice.

Journal of endocrinological investigation·2026
Same journal

Lactobacillus gasseri alleviates type 2 diabetes via modulation of gut microbiota-host metabolic networks.

Journal of endocrinological investigation·2026
Same journal

Rare causes of exogenous Cushing's Syndrome: a challenge for endocrinologists.

Journal of endocrinological investigation·2026
Same journal

Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.

Journal of endocrinological investigation·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Resistant prolactinomas.

V Vasilev1, A F Daly, L Vroonen

  • 1Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium.

Journal of Endocrinological Investigation
|March 17, 2011
PubMed
Summary
This summary is machine-generated.

Resistant prolactinomas, the most common pituitary tumors, do not respond to standard dopamine agonist treatment. Alternative therapies like dose increase, other agonists, surgery, or radiation are explored for these challenging cases.

More Related Videos

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
04:49

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Related Experiment Videos

Last Updated: Jun 3, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
04:49

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Area of Science:

  • Endocrinology
  • Oncology
  • Pituitary Disorders

Background:

  • Prolactinomas are common pituitary tumors, typically responsive to dopamine agonists.
  • A subset of prolactinomas exhibit resistance to standard medical therapy.
  • Resistance is characterized by persistent hyperprolactinemia and lack of tumor shrinkage.

Purpose of the Study:

  • To define resistant prolactinomas.
  • To explore the underlying mechanisms of dopamine agonist resistance.
  • To outline current and potential treatment strategies for resistant prolactinomas.

Main Methods:

  • Literature review of prolactinoma treatment resistance.
  • Analysis of proposed mechanisms for resistance, including dopamine receptor density.
  • Summary of therapeutic options for resistant cases.

Main Results:

  • Resistance is defined by failure to normalize prolactin levels and reduce tumor size.
  • Reduced dopamine receptor density is a key proposed mechanism for resistance.
  • Treatment options include dose escalation, switching agonists, surgery, radiotherapy, and experimental therapies.

Conclusions:

  • Resistant prolactinomas present a significant clinical challenge.
  • Understanding resistance mechanisms is crucial for developing effective treatments.
  • A multimodal approach is often necessary for managing resistant prolactinomas.